Summary of COVID-19 vadadustat studies

1. Bobrow et al., Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)

448 patient vadadustat late treatment RCT: 3% higher mortality (p=1), 16% lower progression (p=0.36), and 8% improved recovery (p=0.6).
RCT 448 hospitalized COVID-19 patients in the USA showing no significant differences with vadadustat.
Mar 2025, NCT04478071, https://clinicaltrials.gov/study/NCT04478071, https://c19p.org/bobrow